Últimas noticias sobre Ovid Therapeutics (NASDAQ:OVID) Bolsa

Ovid Therapeutics

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.

Ovid Therapeutics Inc

Truist Securities analyst Jake Bartlett maintains Cracker Barrel Old (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) with a Hold and raises the price target from $44 to $48.

News

Price Target

Analyst Ratings

CBRL

Truist Securities Maintains Hold on Cracker Barrel Old, Raises Price Target to $48

UBS analyst Michael Lasser maintains Advance Auto Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) with a Neutral and raises the price target from $42 to $44.

UBS Maintains Neutral on Advance Auto Parts, Raises Price Target to $44

The United States has agreed to provide up to $6.6 billion in direct funding to Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) to build advanced chip facilities in the U.S.
The deal aims to enhance domestic semiconductor production and bolster national security by reducing reliance on foreign suppliers, Barron's <a target="_blank" href="https://www.barrons.com/news/us-finalizes-up-to-6-6-bn-funding-for-chip-giant-tsmc-65252814" rel="noreferrer noopener">reports</a>.
The Biden administration announced that Taiwan Semiconductor's investment will attract $65 billion in private capital to establish three state-of-the-art plants in Arizona.
Also Read: <a target="_blank" href="https://www.benzinga.com/tech/24/11/41978712/asml-projects-revenue-surge-to-63-billion-by-2030-eyes-ai-and-chip-market-boom" rel="noreferrer noopener">ASML Projects Revenue Surge to $63 Billion by 2030, Eyes AI and Chip Market Boom</a>
The announcement comes just before President-elect Donald Trump assumes office. Trump had previously attacked Taiwan for allegedly undermining the U.S. chip industry and <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41845483/taiwan-semiconductor-us-expansion-plans-unfazed-by-trump-win-report" rel="noreferrer noopener">criticized the U.S. Chips Act</a>.
The first of Taiwan Semiconductor's facilities will likely commence operations by early 2025, focusing on producing cutting-edge logic chips. These chips will power next-generation technologies, including 5G/6G smartphones, autonomous vehicles, and AI applications.
Early production at the Arizona plant reportedly matches the quality of Taiwan Semiconductor's facilities in Taiwan, showcasing <a target="_blank" href="https://www.benzinga.com/government/24/10/41545709/usa-scores-big-win-taiwan-semiconductor-arizona-plant-sees-good-production-yields" rel="noreferrer noopener">strong initial yields</a>.
Commerce Secretary Gina Raimondo told Barron's the importance of manufacturing these advanced chips domestically, emphasizing their role in AI, quantum computing, and military hardware.
The initiative aims to mitigate risks associated with overseas supply chains by producing these chips on U.S. soil, addressing a critical national security concern.
In addition to the direct funding, the U.S. government is extending up to $5 billion in proposed loans to support Taiwan Semiconductor's Arizona project.
The investment will likely generate approximately 6,000 direct manufacturing jobs. A senior U.S. official told Barron's that at least $1 billion of the allocated funding could be distributed to Taiwan Semiconductor this year, contingent on meeting specific milestones.
Meanwhile, Taiwan Semiconductor remains focused on consolidating its moat while diversifying its footprint beyond Taiwan as global governments dole out attractive subsidies.
The contract chipmaker has <a target="_blank" href="https://www.benzinga.com/markets/emerging-markets/24/11/41951575/taiwan-semi-boosts-advanced-chipmaking-with-record-euv-expansion-grabs-56-global-share" rel="noreferrer noopener">ramped up its</a> deployment of extreme ultraviolet (EUV) lithography systems, a vital technology in semiconductor production, even with the substantial expense involved.
Each EUV machine costs more than $100 million, making them some of the most costly assets in the chip manufacturing sector.
Industry analysts suggest that TSMC has significantly boosted its EUV capacity, increasing its share of global EUV installations from 50% in 2020 to 56% by 2023.
In Asia, Japan has also earmarked over $64.9 billion to <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41939018/japan-increases-semiconductor-funding-as-us-trade-policies-pressure-taiwan-semiconductor" rel="noreferrer noopener">boost the semiconductor and AI</a> sectors. Taiwan Semiconductor is eyeing a second facility in Japan's Kumamoto region, considering a $13.5 billion investment after its first $8.6 billion wafer factory there.
Additionally, the company intends to establish a third advanced chip plant valued at $20 billion in Kumamoto to produce 3-nanometer chips.
Taiwan Semiconductor stock is up 86% year-to-date.
Price Actions: TSM stock is down 1.21% at $186.23 at the last check on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/management/24/11/41978942/salesforce-ceo-marc-benioff-bets-big-on-billion-bots" target="_blank" rel="noreferrer noopener">Salesforce CEO Marc Benioff Bets Big on Billion Bots</a></li>
</ul>
Image via Shutterstock

Government

Regulations

Tech

Media

Just Before Biden's Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants

Truist Securities analyst Michael Lewis maintains American Healthcares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHR#NYSE">AHR</a>) with a Buy and raises the price target from $27 to $29.

Truist Securities Maintains Buy on American Healthcares, Raises Price Target to $29

Benchmark analyst Fawne Jiang reiterates Alibaba Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) with a Buy and maintains $118 price target.

Reiteration

BABA

Benchmark Reiterates Buy on Alibaba Gr Hldgs, Maintains $118 Price Target

<a href="https://www.bloomberg.com/news/articles/2024-11-15/xi-warns-against-going-back-in-history-as-trump-tariffs-loom">https://www.bloomberg.com/news/articles/2024-11-15/xi-warns-against-going-back-in-history-as-trump-tariffs-loom</a>
Chinese President Xi Jinping warned against any efforts to unwind globalization in his first major remarks since Donald Trump won the US presidential election after threatening to impose tariffs as high as 60% on the world's second-biggest economy.

Macro Economic Events

Economics

"Xi Warns Against 'Going Back in History' as Trump Tariffs Loom" - Bloomberg News

Truist Securities analyst Scott Ciccarelli maintains Advance Auto Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) with a Hold and lowers the price target from $41 to $39.

Truist Securities Maintains Hold on Advance Auto Parts, Lowers Price Target to $39

Benchmark analyst Michael Albanese reiterates OneWater Marine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEW#NASDAQ">ONEW</a>) with a Hold.

ONEW

Benchmark Reiterates Hold on OneWater Marine

In a move likely to lighten the load for thousands of retirees in Florida, the state has introduced a new COLA to its property tax exemptions to help seniors cope with <a href="https://www.benzinga.com/real-estate/24/06/39229358/u-s-home-prices-surge-50-jump-in-five-years">rising housing costs</a>.&nbsp;
Currently, eligible homeowners receive two $25,000 exemptions, reducing the taxable value of their primary residence by up to $50,000. With this amendment, the second $25,000 exemption will now grow yearly to mirror inflation – much like Social Security's COLA increase.&nbsp;
Don't Miss:
<ul>
<li>‘Beating the market through ethical real estate investing' —<a href="https://www.benzinga.com/money/invest-with-roots"> this platform aims to give tenants equity in the homes they live in while scoring 17.38% average annual returns for investors – here&#8217;s how to join with just $100</a></li>
<li>This company is giving accredited investors an opportunity to invest in this $2 billion fund, <a href="https://www.benzinga.com/money/ignite-funding">with three decades in business they boast an impressive track record of double-digit returns.</a></li>
</ul>
For retirees feeling the pinch of inflated grocery, health care and utility costs, this tweak could mean real savings that help make ends meet.
Beginning Jan. 1, 2025, Florida&#8217;s homestead exemption – a property tax break on primary homes – will include an inflation-linked increase. In effect, the state will adjust part of the exemption amount annually to keep up with inflation, much like Social Security annually receives a COLA boost.&nbsp;
Trending: During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes"> high-yield real estate notes that pay 7.5% &#8211; 9% are protected by resilient assets, buffering against losses.</a>
By pegging this exemption to inflation, retirees will be protected against property tax increases, which can otherwise eat away at home equity and monthly budgets. The impact of such a policy can be huge. For example, the income limits for eligibility to exemptions rose 4.1% in 2024, widening the reach of the benefit and bringing more retirees under its umbrella.&nbsp;
Supporters see the amendment as a lifeline, especially in a state like Florida, where retirees comprise a significant portion of the population.&nbsp;
The passage of Amendment No. 5 was fueled in part by Florida's rapidly increasing housing costs. Housing prices in the state have shot up in recent years and property taxes that match these prices can quickly become untenable for those on fixed incomes.
See Also: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
On the flip side, not all Florida residents stand to benefit. Property tax relief remains out of reach for <a href="https://www.benzinga.com/real-estate/24/09/40669305/your-landlord-might-be-raising-rent-using-algorithms-and-kamala-harris-plans-to-ban-it-will-she-succ">landlords</a>, for instance, who don't qualify for the exemption. Moreover, some experts fear that as property tax revenue dips, the financial burden might eventually be shifted to nonexempt residents.
Florida's homestead exemption only applies to primary residences, meaning a property must serve as a person's permanent home to qualify for this exemption.&nbsp;
Amendment No. 5 includes a carve-out for schools, ensuring they won't see a dip in property tax revenue due to the new policy. However, all other local governments, such as fire departments and utilities, may need to make up for the shortfall in other ways.
Read Next:
<ul>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Real Estate

Florida Just Introduced A Property Tax COLA For Retirees – How This Boost Could Ease Housing Costs For Thousands

Truist Securities analyst David Macdonald maintains AdaptHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) with a Buy and lowers the price target from $13 to $12.

AHCO

Truist Securities Maintains Buy on AdaptHealth, Lowers Price Target to $12

Benchmark analyst Josh Sullivan reiterates Ultralife (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULBI#NASDAQ">ULBI</a>) with a Buy and maintains $14 price target.

ULBI

Benchmark Reiterates Buy on Ultralife, Maintains $14 Price Target

<a href="https://www.reuters.com/world/europe/germanys-scholz-russias-putin-hold-phone-call-friday-bloomberg-reports-2024-11-15/" title="https://www.reuters.com/world/europe/germanys-scholz-russias-putin-hold-phone-call-friday-bloomberg-reports-2024-11-15/">https://www.reuters.com/world/europe/germanys-scholz-russias-putin-hold-phone-call-friday-bloomberg-reports-2024-11-15/</a>

Macro Notification

General

Putin And Germany's Scholz Hold Phone Call Initiated By Germany, Discuss Ukraine And Middle East; Putin Emphasizes Openness To Ukraine Talks, Notes Degradation In Russia-Germany Relations, And Stresses Security And Territorial Concerns

U.S. stocks were lower, with the Dow Jones index falling around 300 points on Friday.
Shares of Despegar.com, Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) rose sharply during Friday's session after the company reported <a href="https://www.benzinga.com/quote/DESP/earnings">better-than-expected third-quarter sales.</a>
The company said it sees FY24 revenue of at least $760 million and adjusted EBITDA of at least $170 million
Despegar.com shares jumped 19.1% to $17.70 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) shares jumped 43% to $18.98. Bloom Energy announced a 1 GW fuel cell deal with AEP, providing clean power for AI Data Centers.</li>
<li>Red Cat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) gained 22.3% to $4.9200.</li>
<li>Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) gained 13% to $11.56. The company reported third-quarter results on Thursday.</li>
<li>Century Aluminum Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENX#NASDAQ">CENX</a>) rose 12.6% to $23.77.</li>
<li>COMPASS Pathways plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) jumped 12.5% to $5.50.</li>
<li>Lifeway Foods, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWAY#NASDAQ">LWAY</a>) gained 11% to $24.85. The company reported quarterly results on Thursday.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) rose 10.3% to $5.13. Kingsoft Cloud Holdings will release its unaudited financial results for the third quarter before the open of U.S. markets on Tuesday, Nov. 19.</li>
<li>Alcoa Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) gained 7.7% to $44.40.</li>
<li>Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) shares rose 6.3% to $28.34. The company priced a $200 million public offering of 7,843,137 shares at $25.50 per ADS.</li>
<li>Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) gained 6% to $62.72 after the company announced it will transfer its stock exchange listing over to the Nasdaq.</li>
<li>The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) rose 3% to $112.38. The company reported quarterly results on Thursday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42007586/top-4-energy-stocks-that-could-blast-off-in-november">Top 4 Energy Stocks That Could Blast Off In November</a></li>
</ul>

Earnings

Markets

Movers

Trading Ideas

CENX

CMPS

DESP

LUNR

LWAY

PLTR

RCAT

ZLAB

Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday

Options

DKNG

DraftKings Option Alert: Dec 20 $42 Calls At The Ask: 2000 @ $0.89 Vs 1254 OI; Ref=$39.23

WIIM

BNTX

MRNA

NVAX

VALN

Shares of vaccine stocks are trading lower After President-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS.

Prime Minister Keir Starmer is seeking to meet with China&#39;s Xi Jinping at next week&#39;s Group of 20 summit in Rio de Janeiro, in what would be the first face-to-face encounter between British and Chinese leaders in almost seven years.&nbsp;
<a href="https://www.bloomberg.com/news/articles/2024-11-15/uk-s-starmer-seeks-xi-meeting-at-g-20-summit-in-rio-de-janeiro" title="https://www.bloomberg.com/news/articles/2024-11-15/uk-s-starmer-seeks-xi-meeting-at-g-20-summit-in-rio-de-janeiro">https://www.bloomberg.com/news/articles/2024-11-15/uk-s-starmer-seeks-xi-meeting-at-g-20-summit-in-rio-de-janeiro</a>

'UK's Starmer Seeks Xi Meeting at G-20 Summit in Rio de Janeiro' - Bloomberg

Wells Fargo analyst Eric Luebchow maintains Dycom Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DY#NYSE">DY</a>) with a Overweight and raises the price target from $200 to $215.

Wells Fargo Maintains Overweight on Dycom Industries, Raises Price Target to $215

Benchmark analyst Bill Sutherland reiterates HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) with a Speculative Buy and maintains $8 price target.

BEAT

Benchmark Reiterates Speculative Buy on HeartBeam, Maintains $8 Price Target

Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) has dramatically increased its exposure to Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) ETFs, according to its latest 13F filing with the U.S. Securities and Exchange Commission (SEC), reflecting growing <a href="https://www.benzinga.com/24/11/42009965/vaneck-ceo-boldly-predicts-bitcoin-at-300k-per-coin-reaching-half-of-golds-market-cap-in-the-face-of-growing-demand">institutional interest in digital assets.</a>
What Happened: The Wall Street powerhouse <a href="https://www.sec.gov/edgar/search/#/q=Bitcoin&amp;dateRange=custom&amp;category=custom&amp;entityName=Goldman%2520Sachs&amp;startdt=2024-11-14&amp;enddt=2024-11-14&amp;forms=13F-HR">disclosed</a> $710 million invested across multiple Bitcoin exchange-traded funds (ETFs) for the quarter ending September 30. A 13F filing is a quarterly report required by the SEC for institutional investors managing over $100 million in assets.
<h3 class="wp-block-heading">Major Holdings in BlackRock's Bitcoin Trust</h3>
The filing highlights Goldman Sachs&#8217; significant stake in BlackRock's iShares Bitcoin Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>), with 12.7 million shares valued at $461 million. 
This marks an 83% increase from its August holdings of 6.9 million shares, then valued at $281 million, and solidifies Goldman's position as the second-largest holder of IBIT, trailing only Millennium Management, which leads with $844 million in holdings.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42007247/bitcoin-dogecoin-success-driven-by-narrative-and-momentum-report-argues">Bitcoin, Dogecoin Success Driven By &#8216;Narrative And Momentum,&#8217; Report Argues</a>
<h3 class="wp-block-heading">Diversifying Bitcoin ETF Investments</h3>
Goldman also boosted its positions in other prominent Bitcoin ETFs. Notable increases include:
<ul>
<li>Fidelity's Wise Origin Bitcoin ETF (CBOE: FBTC): 1.7 million shares worth $95.5 million, a 13% rise.</li>
<li>Grayscale Bitcoin Trust (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBTC#OTC">GBTC</a>): 1.4 million shares valued at $71.8 million, a 116% increase.</li>
<li>Bitwise Bitcoin ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BITB#NYSE">BITB</a>): 650,961 shares worth $22.5 million, marking a 156% rise.</li>
</ul>
The bank also reported smaller stakes in Bitcoin ETFs offered by Invesco Galaxy, WisdomTree and ARK 21Shares.
<h3 class="wp-block-heading">Institutional Confidence In A Booming Market</h3>
Goldman's expanded investments coincide with record inflows into <a href="https://www.benzinga.com/24/11/41869353/massive-day-for-blackrocks-bitcoin-etf-as-trading-volume-reaches-unseen-levels-with-4-1-billion-traded">spot Bitcoin ETFs.</a> BlackRock's IBIT recently surpassed the iShares Gold ETF (IAU) in net assets, an impressive milestone considering IBIT's launch occurred just this January.
The rising momentum aligns with broader market optimism for a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41770352/bitcoins-future-under-president-elect-donald-trump-a-look-at-his-crypto-policies">pro-crypto regulatory environment</a> under the incoming Trump administration, which has pledged support for crypto mining and a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41986427/pennsylvania-introduces-bitcoin-strategic-reserve-act-to-invest-up-to-700-million-in-btc">national Bitcoin reserve</a>.
Goldman's aggressive moves into Bitcoin ETFs underscore the shifting landscape for digital assets, signaling increasing institutional adoption of cryptocurrency as a mainstream asset class.
To explore these developments further, Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19 offers in-depth insights into the evolving crypto investment landscape.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/11/41996491/18-republican-states-sue-bidens-sec-over-harsh-crypto-crackdown">18 Republican States Sue Biden&#8217;s SEC Over Harsh Crypto Crackdown</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitwise Bitcoin ETF Common Shares of Beneficial Interest

BITB

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

GBTC

IBIT

Goldman Sachs Expands Bitcoin ETF Holdings To $710 Million

Benchmark analyst Fawne Jiang reiterates JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) with a Buy and maintains $47 price target.

Benchmark Reiterates Buy on JD.com, Maintains $47 Price Target

Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome

Ovid Therapeutics ( ($OVID) ) has issued an announcement. Ovid Therapeutics Inc. has promoted Margaret "Meg" Alexander to President and COO, recogn...

Ovid Therapeutics Elevates Meg Alexander to President and COO

BTIG analyst Thomas Shrader maintained a Buy rating on Ovid Therapeutics (OVID – Research Report) yesterday and set a price target of $5.00. Thomas...

Promising Neurology Breakthrough: Ovid Therapeutics' OV329 Shows Safety and Efficacy Potential

Oppenheimer analyst Francois Brisebois maintained a Hold rating on Ovid Therapeutics (OVID – Research Report) today. The company's shares closed ye...

Oppenheimer Sticks to Their Hold Rating for Ovid Therapeutics (OVID)

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on OVID stock, giving a Buy rating on September 27. Ram Selvaraju has giv...

Buy Rating Affirmed for Ovid Therapeutics on Promising Safety Profile and Robust Pipeline Progress

Thomas Shrader, an analyst from BTIG, maintained the Buy rating on Ovid Therapeutics (OVID – Research Report). The associated price target remains ...

Ovid Therapeutics: Promising Safety Profile and Growth Potential Underpin Buy Rating

Reports Q3 revenue $173,000, consensus $90k. "The biopharmaceutical industry is entering an exciting new era of neurotherapeutics, and we are poise...

Ovid Therapeutics reports Q3 EPS (20c), consensus (20c)

Ovid Therapeutics GAAP EPS of -$0.20 misses by $0.01, revenue of $0.17M beats by $0.1M

Ritu Baral, an analyst from TD Cowen, has initiated a new Buy rating on Ovid Therapeutics (OVID). Ritu Baral has given his Buy rating due to a comb...

Ovid Therapeutics: Strategic Developments and Financial Stability Lead to Buy Rating

Wedbush analyst Laura Chico maintained a Buy rating on Ovid Therapeutics (OVID – Research Report) today and set a price target of $4.00. The compan...

Comments

Ovid Therapeutics

Noticias

Últimas noticias sobre Ovid Therapeutics (NASDAQ:OVID) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL